BioAge is a clinical-stage biotechnology company utilizing a proprietary multi-omics platform that analyzes 65 million molecular measurements from 45 years of human aging to identify novel therapeutic targets for metabolic diseases. Its lead program, azelaprag, is an oral APJ agonist entering Phase 2 trials, designed to enhance weight loss and body composition in older adults undergoing obesity treatment with incretin drugs.
Funding
$170M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SIFounders
Product
Problem
Obesity and related metabolic diseases are increasingly prevalent health challenges, particularly among older adults. Current treatments may not provide sufficient weight loss or improvements in body composition, and age is a critical risk factor that complicates effective intervention.
Solution
BioAge is developing azelaprag, an oral APJ agonist, as a potential first-in-class therapy to enhance weight loss and improve body composition in older adults undergoing obesity treatment with incretin drugs. The drug is designed to be co-administered with incretin drugs to achieve injectable-like total weight loss. BioAge utilizes a proprietary multi-omics platform that analyzes molecular measurements from human aging to identify novel therapeutic targets for metabolic diseases, informing the development of pipeline programs targeting key pathways that drive metabolic aging.
Target Audience
The primary target audience includes older adults with obesity or related metabolic diseases who are undergoing treatment with incretin drugs.
Features
- Oral APJ agonist designed to be co-administered with incretin drugs
- Aims to enhance weight loss and improve body composition
- Multi-omics platform analyzes molecular data from human aging
- Identifies novel therapeutic targets for metabolic diseases
- Targets key pathways that drive metabolic aging